Seres Therapeutics, Inc.

Listed Company

MCRBCIK 0001609809NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$789.0K

Net Income

$5.70M

Total Assets

$138.19M

Equity

$44.22M

Shares Out

9.59M

Op. Cash Flow

$1.12M

MCRB$5.35−62.19% · past yearDBEQ Basic

Daily closing prices

Business

Seres Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products (LBPs)—defined consortia of bacteria designed to modulate the human microbiome and treat diseases. The company successfully developed and sold VOWST, the first FDA-approved oral microbiome therapeutic, to Nestlé Health Science in September 2024. Seres' pipeline includes SER-155 for infectious disease and immune-related conditions, SER-603 for inflammatory bowel disease, and SER-147 for chronic liver disease, supported by proprietary discovery platforms, manufacturing capabilities, and clinical development networks.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Grant revenue	789,000	0	0	0	1
Total revenue	789,000	0	0	7	145
Research and development expenses	49	65	118	110	142
General and administrative expenses	39	53	78	70	69
Manufacturing services	7	4	0	0	—
Total operating expenses	95	121	195	180	209
Loss from operations	−94	−121	−195	−180	−64
Gain on sale of VOWST Business	81	6	0	0	—
Interest income	2	4	7	3	3
Interest expense	0	0	−2	−6	−3
Other income (expense), net	17	−14	134,000	−705,000	−1
Total other income (expense), net	100	−4	5	−4	−1
Net income (loss) from continuing operations	6	−126	−190	−184	—
Net income from discontinued operations, net of tax	0	126	76	−67	—
Net income (loss)	6	136,000	−114	−250	−66
Net income (loss) from continuing operations per share attributable to common stockholders - basic	0.64	−16.2	−29.71	−1.7	—
Net income from discontinued operations per share attributable to common stockholders - basic	0	16.2	11.94	−0.62	—
Net income (loss) per share attributable to common stockholders - basic	0.64	0	−17.77	−2.31	−0.72
Net income (loss) from continuing operations per share attributable to common stockholders - diluted	0.64	−16.2	−29.71	−1.7	—
Net income from discontinued operations per share attributable to common stockholders - diluted	0	16.2	11.94	−0.62	—
Net income (loss) per share attributable to common stockholders - diluted	0.64	0	−17.77	−2.31	−0.72
Weighted average common shares outstanding - basic	9	8	6	108	92
Weighted average common shares outstanding - diluted	9	8	6	108	92
Unrealized gain on investments, net of tax of $0	0	0	10,000	49,000	−12,000
Currency translation adjustment	0	0	2,000	−1,000	−1,000
Total other comprehensive income	0	0	12,000	48,000	−13,000
Comprehensive income (loss)	6	136,000	−114	−250	−66

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	46	31	128	163	180
Accounts receivable due from SPN - related party	360,000	2	0	—	—
Accounts receivable	157,000	0	—	—	—
Prepaid expenses and other current assets	3	6	8	13	13
Total current assets	49	39	175	195	304
Property and equipment, net	8	12	18	23	18
Operating lease assets	72	81	90	111	18
Restricted cash	9	9	8	8	8
Other non-current assets	31,000	31,000	2	10	5
Total assets	138	140	359	349	355
Accounts payable	2	4	4	17	14
Accrued expenses and other current liabilities	4	11	23	60	45
Accrued liabilities due to SPN - related party	3	18	0	—	—
Operating lease liabilities	10	9	6	4	7
Total current liabilities	19	41	99	86	82
Operating lease liabilities, net of current portion	73	83	92	108	18
Other long-term liabilities	2	2	2	1	11
Total liabilities	94	126	403	338	223
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 360,000,000 shares authorized at December 31, 2025 and 2024, respectively; 9,556,446 and 8,650,227 shares issued and outstanding at December 31, 2025 and 2024, respectively	10,000	9,000	135,000	125,000	92,000
Additional paid-in capital	1,017	992	933	875	746
Accumulated deficit	−972	−978	−978	−865	−614
Total stockholders' equity	44	14	−45	11	132
Total liabilities and stockholders' equity	138	140	359	349	355

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	11	21	34	25	20
Depreciation and amortization expense	4	5	6	7	6
Non-cash operating lease cost	8	9	9	5	3
Net (accretion) amortization of (discounts) premiums on investments	0	0	−236,000	688,000	498,000
Gain on sale of VOWST Business, net of transaction costs	0	−147	0	0	—
Amortization of debt issuance costs	0	1	1	705,000	3
Loss associated with extinguishment of debt	0	23	2	0	0
(Gain)/loss on disposal of fixed assets	−192,000	317,000	0	0	—
Impairment of long-lived assets	0	3	0	0	—
Change in fair value of warrant liabilities	0	−546,000	−2	0	0
Collaboration (profit) loss sharing - related party (1)	0	0	5	1	—
Accounts receivable due from SPN - related party	2	−2	0	0	—
Prepaid expenses and other current and non-current assets	3	987,000	−29	−13	−12
Accounts receivable	−157,000	0	0	0	9
Collaboration receivable - related party	0	9	−9	0	0
Inventories	0	−34	−30	0	0
Deferred income - related party	0	−4	8	0	0
Deferred revenue - related party	0	0	−1	−7	−4
Accounts payable	−2	−3	−12	2	9
Accrued liabilities due to SPN - related party	−14	−16	0	0	—
Operating lease liabilities	−9	−6	−2	−4	−4
Accrued expenses and other current and long-term liabilities	−7	−10	16	3	43
Net cash provided by (used in) operating activities	1	−149	−117	−229	7
Purchases of property and equipment	−252,000	−380,000	−8	−10	−10
Proceeds from sales of property and equipment	210,000	0	0	—	—
Purchases of investments	0	0	−4	−48	−96
Sales and maturities of investments	0	0	23	140	170
Sales of restricted investments	0	1	0	0	—
Proceeds from sale of VOWST Business	0	141	0	0	—
Net cash (used in) provided by investing activities	−42,000	142	11	82	64
Proceeds from at the market equity offering, net of issuance costs	13	24	18	4	0
Proceeds from exercise of stock options	501,000	0	877,000	966,000	1
Proceeds from Securities Purchase Agreement - related party	0	14	0	0	—
Issuance of common stock under ESPP	230,000	487,000	2	2	827,000
Proceeds from issuance of debt, net of issuance costs	0	0	103	28	0
Repayment of notes payable	0	−128	−53	−2	−948,000
Net cash provided by (used in) financing activities	14	−90	72	130	1
Net increase (decrease) in cash, cash equivalents and restricted cash	15	−97	−35	−17	72
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0	−1,000	2,000	−1,000	−1,000
Cash paid for interest	0	11	13	5	2
Property and equipment purchases included in accounts payable and accrued expenses	0	0	16,000	2	874,000
Lease liability arising from obtaining right-of-use assets	0	0	3	91	12
Prepaid rent reclassified to right-of-use assets	0	0	5	7	0
Recognition of warrant liabilities	0	0	2	0	0
Warrants issued related to prior credit facility with Oaktree and recorded as debt discount	0	0	3	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Seres Therapeutics, Inc.'s CIK number?

Seres Therapeutics, Inc.'s SEC CIK number is 0001609809 (1609809). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Seres Therapeutics, Inc.'s SEC filings?

All of Seres Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Seres Therapeutics, Inc. last report earnings?

Seres Therapeutics, Inc. (MCRB) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-205009). This is Seres Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Seres Therapeutics, Inc.'s most recent earnings 8-K?

Seres Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-205009. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Seres Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →